However, when combining pterostilbene1 with the third-generation TKI osimertinib (of which IC50s were previously determined, and can be found in Figure 2A), we obtained synergistic results in all EGFR-mutation positive NSCLC cell lines investigated, with a combination index (CI) ranging from 0.63 to 0.70 (Figure 2B). Here, EGFR is linked to non-small cell lung carcinoma.